Amos Hedt

Amos Hedt has a diverse work experience in the biotechnology and pharmaceutical industry. Amos is currently the Chief Business Strategy Officer at Perspective Therapeutics since March 2023. Prior to this, they held the same role at Viewpoint Molecular Targeting, Inc. starting in July 2021.

Before joining these companies, Amos was a Principal Consultant at Cedalion from April 2012, where they provided strategic consulting services for biotechnology, pharmaceutical, and radiopharmaceutical translational product development programs. Amos was responsible for project management and guiding projects from early stage conception to clinical development.

Amos also worked at Clarity Pharmaceuticals as the Head of Clinical Development and Strategy. During their tenure from December 2013 to April 2020, they played a crucial role in the company's focus on personalized medicine and development of targeted therapies for the treatment of cancer and other serious diseases.

Prior to that, Amos served as the Senior Director of Clinical Operations at Patrys Limited from April 2008 to March 2012. Amos also worked as a Clinical Study Manager at CSL Limited from February 2003 to April 2008.

Their career in the industry began as a Clinical Research Associate at Amrad, where they worked from 2001 to 2003.

Overall, Amos Hedt has gained extensive experience in strategic business planning, clinical operations, project management, and consulting in the biotechnology and pharmaceutical field.

Amos Hedt has a Bachelor of Arts (B.A.) in Psychophysiology and Psychology from Swinburne University of Technology. Amos also has a PGradDip and a GradDipArts in History and Philosophy of Science from the University of Melbourne.